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Background: The current Ebola Virus Disease (EVD) outbreak in West Africa is the largest in history. As of February
18th 2015, 23,258 cases of EVD have been cumulatively reported from Nigeria, Senegal, Guinea, Liberia, Mali, Sierra
Leone, Spain, the United Kingdom and the United States of America resulting in more than 9,000 deaths. It is
therefore exigent to develop prevention and treatment therapies for EVD.
Discussion: Several new EVD treatments are in clinical development at this time. Based on lessons learned, four critical
processes need to be implemented before clinical trials begin. First, all global EVD research need to be coordinated to
promote data sharing and synergistic overlap, while reducing unnecessary duplication of efforts. The World Health
Organization is well-placed to undertake such an endeavor. Second, governments of affected nations where trials are
being proposed need to lead discussions regarding immediate access to any proven medications for epidemics. Also,
governments need to leverage international resources to support and expand existing national expertise to jointly
conduct high-caliber clinical research; and resources must be used to enhance local technical skills and expand existing
personnel. Third, ethics committees must review protocols, monitor the research process, and work closely with
research scientists to insure the ethical integrity of research throughout the trials. Fourth, community advisory boards
(CAB) need to be formed, linked with existing community leadership structures and organized in conjunction with trial
implementation. These community structures should work together with ethics committees to facilitate the study
design, informed consent process, and study implementation.
Summary: We must facilitate communication and mutual understanding between trial communities and research
teams, and promote positive collaborations between all stakeholders engaged in EVD research. The community
engagement process for EVD research is crucial to address myths and misconceptions, and to promote study
volunteers’ understanding of the research details. The collaboration between all stakeholders is crucial for continued
long term partnership to address EVD outbreak and none of the stakeholders should be left behind in ongoing efforts
to develop EVD therapies.
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The current Ebola Virus Disease (EVD) outbreak in West
Africa has stimulated renewed interest in the development of
treatment and vaccines. As of February 18th 2015, 23,258
cases of EVD have been reported in Nigeria, Senegal, Guinea,
Liberia, Mali, Sierra Leone, Spain, the United Kingdom and
the United States of America, with a total of 9,380 deaths [1].* Correspondence: toyinukpong@yahoo.co.uk
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creativecommons.org/publicdomain/zero/1.0/Accordingly there is a sense of urgency to develop therapies
to curtail the epidemic. Four critical processes need to be
implemented for EVD clinical trials in affected countries: 1)
government collaboration in countries that host EVD trials
with study sponsors to ensure future access to developed
products; 2) collaboration between local researchers and
their Northern counterparts to ensure transfer of research
capacity; 3) development of competent local ethics commit-
tees; and 4) empowerment of community members to
actively engage in research design and implementation.
Stakeholder engagement in research helps to ensure
prompt translation of research findings into policies andrticle distributed under the terms of the Creative Commons Attribution License
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research, EVD drug discovery needs to be conducted
while the epidemic is ongoing. This brings a sense of
urgency for EVD research protocol approval and study
implementation, which may increase the likelihood of
neglecting stakeholder engagement. This article high-
lights the merits of creating significant institutional re-
lationships with the four key stakeholders – World
Health Organization, national governments, researchers
and community members - critical to the conduct of
EVD trials, and discusses mechanisms to facilitate these
engagement processes.Discussion
Coordination of the global Ebola response
There are several lessons learned about stakeholder en-
gagement in clinical trials from the HIV field. First, all
clinical research needs to be coordinated to reduce du-
plication of effort, promote data sharing, and facilitate
research synergy. Despite the criticism that the World
Health Organization (WHO) was slow to recognise and
respond to the EVD outbreak in West Africa, the agency
remains well placed to provide this pivotal coordinating
function as an established and acceptable international
authority in the region [2]. WHO can facilitate global
communication with research consortiums working on
EVD research in the region in order to avoid duplication
of research efforts, while ensuring rapid information
sharing and evaluation of research results.
WHO has an Advisory Group on EVD that provides
ongoing independent guidance on the strategic response
for outbreaks, with multiple technical guidelines on pre-
vention, treatment and the public health response [3].
WHO has also conducted trainings in collaboration with
national and international partners through the support
of the United Nations’ Mission for Ebola Emergency
Response, in order to achieve the goal of getting 70% of
cases isolated and treated, and 70% of the deceased
safely buried within 60 days [3]. In addition, they have
provided technical support for EVD vaccine access and
financing and accelerated development and deployment
of rapid, easy-to-use diagnostic tools for EVD [3].
One critical role WHO needs to play in the future is
to be stronger and more proactive in its support for
national governments of countries that report EVD out-
breaks. While the current West Africa epidemic has
been acknowledged as unprecedented in magnitude and
scope [4], past epidemics also claimed lives [5] and had
less international attention. It is important to maintain
current EVD surveillance so that both infection and case
fatality rates are reduced in future outbreaks in Africa
and in other parts of the world. WHO also needs to
work in collaboration with the governments of affectednations to ensure prompt access to EVD therapeutic and
preventive medications when needed in future epidemics.
Responsibility of the governments of EVD affected nations
The active engagement of national governments of African
nations is required to promote ownership of the response.
Their actions could also provide the incentive to invest in
the research process, which would bring with it capacity
development opportunities for local researchers. Unfortu-
nately, the level of government investment in research in
these countries is low, as is the number of researchers
who can successfully design and implement clinical trials
or access research funding [6]. Governments need to sup-
port the development of indigenous competence in order
to address the shortage of local expertise. Specifically there
is a need to increase local researchers’ ability to conduct
cutting-edge research, including clinical trials, leveraging
international resources available for current EVD research.
Funding should be dedicated to developing a critical mass
of skilled researchers who could lead locally relevant
health research.
Considering that research regulation is in its infancy in
the region [7], support for the development and strength-
ening of institutions, systems, and mechanisms that would
engender robust research regulation regimes in affected
countries is essential. Research regulatory policies help
promote ethical research conduct. The benefits of devel-
oping necessary research regulation infrastructure can be
sustained long after the current epidemic. For many coun-
tries, it is not the enactment of policies and legislations
that is the challenge, but their implementation. Research
ethics committees may face challenges monitoring re-
search, even when mandated by government [8]. Yet
ensuring local oversight of EVD research is essential to
fostering trust in the EVD research enterprise. Multiple
approaches for conducting research monitoring should be
explored [9]. Mechanisms instituted through the develop-
ment of local research monitoring competence would be
an enduring legacy for each country.
The decision to engage Institutional Ethics Review
Committees or National Ethics Review Committees to re-
view EVD related research protocols must be determined
by the national policies and guidelines that govern research.
Frequently, research projects that are of profound national
interest are reviewed by National Ethics Review Commit-
tees rather than Institutional Ethics Review Committees.
The tension and ensuing controversies between the
National Ethics Committee and an Institutional Review
Ethics Committee in Malawi over protocol determination
for an antiretroviral based research project is an example of
why guidelines need to be clear [10]. Therefore, the regula-
tory research structures in EVD affected countries must be
reviewed and where needed, guidelines should be revised
regarding how to handle EVD research protocols. Systems
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Review Committees and Institutional Ethics Review Com-
mittees also need to be defined where these do not exist.
Active engagement of governments would also enable
governments of low-income countries to engage and pro-
mote early discussions regarding immediate and affordable
access to any proven medications for future epidemics
through effective mechanisms. It is essential that any ef-
fective medications developed are made available through
tiered pricing systems accessible by low income countries
and delivered through health systems that are strength-
ened to facilitate distribution [11]. However, since tiered
pricing systems have their own operational challenges, na-
tional governments should also try negotiating to obtain
the drugs for free or at cost if possible.
In essence, governments need to plan for catastrophic
infectious disease outbreaks as they would prepare for
disaster management, which entails developing systems
of surveillance, environmental management, capacity to
manage humane quarantine, and provision of medical
services for the sick. International non-governmental or-
ganizations (NGOs) need to work with governments to
build local capacity in each of these areas.
Foreign governments and donors also have responsi-
bilities. Rid and Emmanuel [12] discussed the ethical
imperative for high-income countries to support mecha-
nisms for ensuring prompt future access to medication(s)
for low-income countries. Studies on the prevention of
HIV, tuberculosis and malaria in Africa and Asia have been
heavily supported by developed countries. We have also
observed the same for a few other tropical diseases like the
eradication of Guinea worm infection in Nigeria and the
improvement in maternal and child health in Africa. Simi-
lar support and outcomes would be expected for EVD.
While health system strengthening may be a primary
need for countries currently experiencing EVD outbreaks,
it is important to start addressing how high-income coun-
tries can support future access to Ebola medication(s)
through fair policies regarding the trade of essential phar-
maceuticals. The engagement and commitment of Global
Access to Vaccines Initiative (GAVI) to facilitate future
EVD vaccine access in affected countries [13, 14] is com-
mendable. Still, there is a need to further explore mecha-
nisms that would promote long term independent access
of resource-poor countries to EVD vaccines, therapies and
diagnostics. This would require that WHO broker the
process of having researchers, drug developers and na-
tional governments institute legally binding contracts be-
fore the trials commence, to stipulate how nations would
have access to the developed vaccines and medications.
Responsibilities of African researchers
As the competency to conduct clinical trials in many
African countries is currently low, African scientistswithin the continent and in the diaspora need to do
more to build research competency in the region. This
need in developing countries has dominated many
discussions and initiatives of North–South collaborations.
African researchers who have been and continue to be
part of such research capacity strengthening initiatives
need to actively engage in the current effort to conduct
basic science, clinical, epidemiological, social science and
operations research about EVD prevention, management
and control in the region. Efforts should be made to foster
more North–South and South-South collaborations for
this purpose.
Community engagement and EVD research
Active community engagement is required as a strategy
to foster collaborative partnership and social value of the
study for the participant communities [15]. However, the
notion of ‘community’ has often been too loosely applied
with the risk that those eventually engaged for study
purposes are not true representatives of the research
participants and their communities. To ensure that com-
munity collaboration processes are effective, we propose
the adoption of guidelines developed to facilitate mean-
ingful community engagement during HIV prevention
research [16–18]. This involves actively building rela-
tionship between researchers, communities and other
stakeholders, and developing mechanisms that enable
community members to have real collaborative decision-
making power in the research process. The active en-
gagement of community members in study design and
implementation prevents misunderstanding of the goals
and processes of research, and helps strengthen science
through improving acceptability and understanding of
the research, improving the ethics of international col-
laborative research, countering misconceptions, and in-
creasing familiarity with and trust in trial staff [19].
Community engagement during EVD research especially
in the time of an epidemic can address myths and mis-
conceptions that study participants are being exploited.
Engaging the community can facilitate their understand-
ing of the difference between research procedures and
therapy [20]. The prospect for therapeutic misconception
is also high and so research literacy efforts are required to
prevent erroneous beliefs that instances of deaths or re-
covery during trials is necessarily the result of the experi-
mental therapy. It is important that research teams engage
with existing community structures to promote research
literacy efforts by enhancing public discussions and under-
standing of national EVD research plans.
Formal community engagement can be achieved through
the formation of community advisory boards (CABs). A
CAB is composed of community members who share a
common health concerns, history, symbols and language,
and culture [21]. Their involvement in research may greatly
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study implementation, particularly those targeting vulner-
able populations. A community with low research literacy
such as those in regions affected by EVD is considered
vulnerable to research exploitation, making community
engagement in EVD research more crucial.
It is important to acknowledge that in the wake of the
EVD outbreak, communities have also responded by re-
organizing themselves to ensure their protection and
survival. For example, in the EVD affected regions, EVD
survivors are organizing themselves into groups with the
aim of addressing their particular needs such as address-
ing post-traumatic stress disorder, stigma, nutritional
and housing needs; as well as engaging with the EVD re-
sponse in their country [22]. EVD survivors would be
excellent resource persons to work with during the de-
sign and implementation of EVD research.
While the engagement of representatives of communi-
ties and CABs may facilitate the perceived legitimacy of
research, other factors need to be considered in forming
‘representative’ bodies for consultations. For example, it
may be necessary also to engage stakeholders with ex-
pertise in infectious disease epidemics and who are fa-
miliar with the difficulties of undertaking research in
such circumstances. This suggests that the membership
of the CAB could include key stakeholders in the EVD
response, those with higher research literacy and wider
exposure to research (academicians, health practitioners,
literate community members), and representatives of
NGOs working in the area alongside representatives
from the participant’s population such as EVD survivors.
The effectiveness of CABs within HIV research dem-
onstrates the benefits of engaging communities with
drug research and development, as articulated by West
Slevin et al. [23]. With HIV treatment trials, CABs were
composed of AIDS activists many of whom needed ef-
fective treatment to live. They were invested in promot-
ing drug development for the management of HIV
infection. This resulted in expedited review and approval
of HIV drugs in the early 2000s. With HIV prevention
research, CABs have been composed of more diverse
people and have not been able to mobilise for stake-
holder investment as effectively as it happened with HIV
treatment activists [23]. With EVD research, it is advis-
able that the CABs should be composed of community
members who feel ‘ strongly’ about the need to be dir-
ectly engaged with the research and drug development
process. This can lead to more significant impacts with
the research and drug development process as was wit-
ness with the HIV treatment movement.
Engagement of the ethics review committee
Conducting meaningful community engagement for EVD
research during the current epidemic may be challengingin view of the urgent need to develop some forms of ther-
apy that can help reduce case fatality. This scenario may
promote the view that there is little time for extensive
community consultative processes prior to commence-
ment of research, unlike what happens for HIV prevention
research. In the face of the current urgency, Folayan et al’s
[24] proposal for community engagement for genomic re-
search may be adopted as an alternative mechanism: ef-
forts can be invested to indirectly engage communities in
the design and implementation of EVD research through
the engagement of laypersons on ethics committees.
Laypersons are a ‘specialized’ subset of the community
who actively participate in the administration of research
protocols through their work on ethics committees. They
can review protocols and provide constructive feedback
that address community needs and concerns. This ap-
proach would require building the capacity of laypersons
to review research protocols and address community con-
cerns [25]. Where such capacity does not exist, this interim
measure may not be a viable option.
Stakeholder dialogue
It is important to ensure that stakeholder engagement is
not done in silos. There is the need for effective communi-
cation mechanisms between different actors and players
involved with the EVD response within countries affected
by the outbreak, between countries in the EVD region and
with other international stakeholders. Effective stakeholder
engagement and dialogue can be facilitated using multiple
media (tele-conferences, webinars, online dialogue) to
promote sharing of best practices within and between af-
fected countries and regions [26, 27]. Face to face commu-
nity dialogue is equally important for facilitating
discussions on EVD research in local communities [28,
29]. The current armamentarium of tools to facilitate
intra- and inter- stakeholder communications can be har-
nessed to promote timely engagement between relevant
stakeholders engaged with the EVD response.
Summary
A coordinated local, regional and international response
to the epidemic is essential. While there is a sense of ur-
gency to develop therapies for the current EVD epidemic
and to marshal available resources for the conduct of
research on EVD [30–32], coordinated efforts should
take place to ensure that international and local rules,
laws and norms governing research are respected, ex-
ploitation of research participants is avoided and the
EVD research process does not negatively impact upon
patients and their support systems. This is important in
view of the history of mistrust as the aftermath of civil
wars in the West African region [33]. The collaboration
between all stakeholders is crucial for continued long
term partnership to address EVD outbreak and no one
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develop EVD therapies.
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